Atara biotherapeutics presents positive preclinical data on ata3431, a next-generation allogeneic cd20/cd19-targeted car, at the 65th ash annual meeting

Thousand oaks, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data on ata3431, a next-generation allogeneic cd20/cd19-dual targeted chimeric antigen receptor (car) ebv t-cell therapy candidate. findings support ata3431 advancement into clinical testing, in.
ATRA Ratings Summary
ATRA Quant Ranking